source
- Alumis' TYK2 lupus drug fails mid-stage trial, CEO says clear path forwardAlumis announced that its TYK2 inhibitor did not meet primary endpoints in a mid-stage study in patients with lupus. The trial, which was the company's lead program, was designed to evaluate effic…
- K Health plans IPO by 2029 after recent funding roundK Health, a virtual‑care company that uses AI, announced its intention to go public by 2029. CEO Allon Bloch made the comment after a recent fundraising round, signalling the firm is preparing for…